OPK OPKO Health Inc.

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15th at 3:00 p.m. Pacific time.

The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website .

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit .

Contacts:

Alliance Advisors IR

Yvonne Briggs, 310-691-7100



or

Bruce Voss, 310-691-7100



EN
09/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OPKO Health Inc.

 PRESS RELEASE

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advan...

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financ...

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study () of an EBV vaccine candidate being deve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch